

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Rs. in Lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	15,370	15,358	13,060	45,506	39,432	51,281
2 Other Income	192	183	51	556	296	480
3 Total Income (1+2)	15,562	15,541	13,111	46,062	39,728	51,761
4 Expenses						
(a) Cost of Materials Consumed	2,485	3,730	2,026	9,262	6,370	8,612
(b) Purchases of Stock-in-Trade	1,649	1,311	2,539	4,626	7,179	9,205
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	683	(567)	(318)	421	(411)	(730)
(d) Employee Benefits Expense	3,369	3,359	2,829	10,007	8,329	11,706
(e) Finance Costs	14	10	7	31	26	31
(f) Depreciation and Amortisation Expense	414	423	391	1,258	1,161	1,550
(g) Other Expenses	3,394	3,796	3,063	10,447	9,287	12,219
Total Expenses	12,008	12,062	10,537	36,052	31,941	42,593
5 Profit before tax (3-4)	3,554	3,479	2,574	10,010	7,787	9,168
6 Income tax expenses						
a. Current Tax	950	967	692	2,709	2,066	2,435
b. Deferred Tax	(42)	(74)	(29)	(141)	(8)	(31)
Total Tax Expenses	908	893	663	2,568	2,058	2,404
7 Profit for the period (5-6)	2,646	2,586	1,911	7,442	5,729	6,764
8 Other Comprehensive Income						
(i) Items that will not be reclassified to Profit or Loss	2	3	(9)	7	(27)	9
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	(1)	3	(3)	7	(2)
Other Comprehensive Income Net of Tax	1	2	(6)	4	(20)	7
9 Total Comprehensive Income for the period (7+8)	2,647	2,588	1,905	7,446	5,709	6,771
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						29,437
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):						
(a) Basic (in Rs.)	16.00	15.64	11.56	45.00	34.64	40.90
(b) Diluted (in Rs.)	16.00	15.64	11.56	45.00	34.64	40.90

Notes:

- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee at its meeting held on January 31, 2024 and have been approved by the Board of Directors at its meeting held on February 01, 2024.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Previous period's figures have been regrouped/reclassified wherever necessary.

For RPG Life Sciences Limited

Yugal Sikri
DIN: 07576560
Managing Director
Mumbai, February 01, 2024